Your browser doesn't support javascript.
loading
Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.
Mweempwa, Angela; Xu, Huiling; Vissers, Joseph H A; Tothill, Richard W; Pattison, Andrew D; Fellowes, Andrew P; Thomas, David M; Richardson, Gary; Hicks, Rodney J; Grimmond, Sean M; Fox, Stephen B; Luen, Stephen J; Desai, Jayesh; Solomon, Benjamin J.
Afiliación
  • Mweempwa A; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Xu H; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Vissers JHA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Tothill RW; Department of Clinical Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia.
  • Pattison AD; Centre for Cancer Research and Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.
  • Fellowes AP; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Thomas DM; Centre for Cancer Research and Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.
  • Richardson G; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Hicks RJ; Centre for Cancer Research and Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.
  • Grimmond SM; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Fox SB; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Luen SJ; The Kinghorn Cancer Centre and Cancer Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Desai J; Cabrini Health, Department of Medical Oncology, Malvern, Victoria, Australia.
  • Solomon BJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
JCO Precis Oncol ; 5: 1160-1165, 2021 11.
Article en En | MEDLINE | ID: mdl-34994633
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feocromocitoma / Pirazoles / Piridinas / Neoplasias de las Glándulas Suprarrenales / Proteínas Proto-Oncogénicas c-ret / Septinas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: JCO Precis Oncol Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feocromocitoma / Pirazoles / Piridinas / Neoplasias de las Glándulas Suprarrenales / Proteínas Proto-Oncogénicas c-ret / Septinas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: JCO Precis Oncol Año: 2021 Tipo del documento: Article País de afiliación: Australia